552330-87-7

Usage

Uses

Used in Organic Synthesis:
6-bromocinnolin-4(1H)-one is used as a building block in organic synthesis for the creation of more complex chemical compounds. Its unique structure and properties make it a valuable component in the synthesis of various organic molecules.
Used in Pharmaceutical Applications:
6-bromocinnolin-4(1H)-one is utilized in the development of drugs due to its potential pharmaceutical applications. Its structure and properties contribute to the discovery and design of new therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-bromocinnolin-4(1H)-one is employed for its importance in drug discovery. Its cinnoline ring system and functional groups provide a foundation for the development of novel compounds with potential therapeutic effects.
Used in Drug Development:
6-bromocinnolin-4(1H)-one is used as a starting material in drug development, where its chemical properties can be modified to create new pharmaceutical agents with specific therapeutic targets and improved efficacy.
Used in Chemical Research:
6-bromocinnolin-4(1H)-one is also used in chemical research to study the properties and reactions of cinnoline derivatives. This research contributes to the understanding of the structure-activity relationships and the development of new synthetic methods for these compounds.

InChI:InChI=1/C8H5BrN2O/c9-5-1-2-7-6(3-5)8(12)4-10-11-7/h1-4H,(H,11,12)

Upstream product

• 61588-11-2 6-bromo-4-oxo-1,4-dihydro-3-cinnolinecarboxylic acid 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 29124-64-9 N-(2-acetyl-4-bromophenyl)acetamide 
• 551-93-9 2-aminoacetophenone 
• 5234-26-4 N-(2-acetylphenyl)acetamide 
• 90484-39-2 (4-bromo-phenylhydrazono)-malonic acid 
• 90271-82-2 (4-bromo-phenylhydrazono)-malonyl chloride 
• 20357-04-4 (5-bromo-2-nitro-phenyl)-propiolic acid 
• 624-19-1 4-bromoaniline hydrochloride 
• 13631-76-0 (4-bromo-phenylhydrazono)-malonic acid diethyl ester 

Downstream Products

• 68211-13-2 4,6-dichlorocinnoline 
• 68211-15-4 6-bromo-4-chlorocinnoline 
• 318276-72-1 6-bromocinnoline 
• 872284-86-1 6-bromo-3-chloro-1H-cinnolin-4-one 

Relevant academic research and scientific papers

Thiazolidine derivatives or salts thereof as an active ingredient an inhibitor Pim

PROBLEM TO BE SOLVED: To provide compounds which have excellent Pim inhibitory action and are useful as pharmaceuticals.SOLUTION: A compound is a thiazolidine derivative represented by the general formula (1) in the figure, or a salt thereof. (In the formula, X represents O or S; Rrepresents a hydrogen atom or a Calkyl group; Z, Z, Z, Z, Zand Zeach independently represent CH or N; Y represents an optionally substituted, divalent Caromatic hydrocarbon group or the like; Am represents a disubstituted amino group, or an optionally substituted, nitrogen-containing saturated heterocyclic group; and Rand Reach independently represent a hydrogen atom, a halogen atom, an alkyl group or the like.)

Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR

The identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cell assays, and good pharmacokinetic profile. Furthermore, compound 31 demonstrated in vivo efficacy in a PC-3M tumor xenograft model.

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

PROTOZOAN PARASITE GROWTH INHIBITORS

Compounds and methods for inhibiting growth of a protozoan parasite. Methods of treating a protozoan parasite infection in a subject by administering a therapeutically effective amount of a compound as disclosed herein. The compounds and methods can be us

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors

A series of heteroaryl-pyridine containing inhibitors of Akt are reported. The synthesis and structure-activity relationships are discussed, leading to the discovery of a indazole-pyridine analogue (Ki = 0.16 nM). These compounds bind in the ATP binding site, are potent, ATP competitive, and reversible inhibitors of Akt activity. No selectivity amongst the Akt isoforms is observed for this analogue, but there is good selectivity against an panel of other kinases. It is least selective for other members of the AGC family of kinases but is nonetheless 40-fold selective for Akt over PKA. The compound shows cellular activity and significantly slows tumor growth in vivo.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.